Method of producing a nanoporous surface for use in medical devices

WO2026217868A3PCT designated stage Publication Date: 2026-11-12NANOVIS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/023156
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-11
Filing Date
2026-04-10
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Magnesium-based implants generate harmful hydrogen gas and trigger inflammatory responses due to complement activation during biodegradation, while titanium alloys release bio-unfriendly elements like aluminum and vanadium, affecting cell adhesion and proliferation.

Method used

Anodizing magnesium-containing or titanium metal alloy substrates in an acidic solution with a controlled voltage to create nanoporous structures with specific geometries, reducing hydrogen gas formation and complement activation.

Benefits of technology

The nanoporous substrates significantly reduce hydrogen gas formation and complement activation, enhancing biocompatibility and osteoconductivity, thereby improving implant efficacy and bone healing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026023156_12112026_PF_FP_ABST
    Figure US2026023156_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A method comprising: providing a substrate, wherein the substrate is a magnesium-containing substrate or a titanium metal alloy-containing substrate; placing the substrate in an acidic solution; covering the substrate in the acidic solution; and applying a voltage to the substrate, thereby producing a nanoporous substrate. In some embodiments, the nanoporous substrate may be a medical device; the magnesium-containing substrate may comprise magnesium oxide; and / or the titanium metal alloy-containing substrate may comprise Ti6Al4V.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No. 2891.099AWOMETHOD OF PRODUCING A NANOPOROUS SURFACE FOR USE IN MEDICAL DEVICESCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit of U.S. Provisional Application No. 63 / 787,167 filed April 11, 2025, which is hereby incorporated by reference in its entirety.FIELD

[0002] The present disclosure relates generally to surfaces and surface coatings for medical devices and methods for producing the same. More specifically, the present disclosure relates to anodized, nanoporous compositions and surface coatings.BACKGROUND

[0003] Biodegradable implants can be placed into human tissue for a variety of purposes, for example, to repair bone fractures. Magnesium exists naturally in human bone, and can serve as a biocompatible, osteoconductive implant material. Magnesium-based biodegradable implants may offer improvements over traditional implants. However, there remain challenges with magnesium-based implants as they may produce an inflammatory response at the implantation site or generate harmful hydrogen gas formation when the implant biodegrades.

[0004] Some titanium metal alloys are considered biodegradable, for example, Ti6A14V, which comprises titanium, aluminum, and vanadium. Titanium metal alloys may be used to provide strong, durable, and biocompatible implants. Ti6A14V may release bio unfriendly elements, such as aluminum and vanadium, thereby causing harmful effects, such as negatively impacting cell adhesion and proliferation.

[0005] The present disclosure is directed to overcoming these and other deficiencies in the art.SUMMARY

[0006] In an aspect, provided is a method, including: providing a substrate, wherein the substrate is a magnesium-containing substrate or a titanium metal alloy-containing substrate;Docket No. 2891.099AWOplacing the substrate in an acidic solution; covering the substrate in the acidic solution; and applying a voltage to the substrate, thereby producing a nanoporous substrate.

[0007] In some embodiments, the nanoporous substrate is a medical device; a non-limiting example of a medical device is a medical implant. In some embodiments, the nanoporous substrate is a medical implant. In some embodiments, the medical implant is biodegradable.

[0008] In some embodiments, the substrate is a magnesium-containing substrate; a nonlimiting example of a magnesium-containing substrate is magnesium oxide. In some embodiments, the substrate is a titanium metal alloy-containing substrate; a non-limiting example of a titanium metal alloy-containing substrate is Ti6A14V.

[0009] In some embodiments, the nanoporous substrate includes a plurality of nanotubes. In some embodiments, the plurality of nanotubes have a wall thickness of about 1 nm to about 53 nm, a depth of about 1 nm to about 2130 nm, and / or an aspect ratio, defined as (nanotube long dimension / nanotube short dimension), of about 0.3 to about 5.

[0010] In some embodiments, the acidic solution includes a fluoride-containing acid; nonlimiting examples of a fluoride-containing acid include hydrofluoric acid and fluoroantimonic acid. In some embodiments, the acidic solution includes 1.5% hydrofluoric acid.

[0011] In some embodiments, the voltage is in a range of about 1 volt to about 25 volts. In some embodiments, the voltage is 20 volts.

[0012] In some embodiments, the substrate includes a film, wherein the film has a thickness of about 10 microns.

[0013] In some embodiments, covering includes covering the substrate in the acidic solution for about 1 minute to about 60 minutes. In a non-limiting example, covering includes covering the substrate in the acidic solution for about 15 minutes.

[0014] In an aspect, provided is an implant, including: a nanoporous substrate, wherein the nanoporous substrate includes a plurality of nanotubes. In some embodiments, the implant is biodegradable.

[0015] In some embodiments, the nanoporous substrate is a nanoporous magnesium-containing substrate; in a non-limiting example, the nanoporous magnesium-containing substrate comprises magnesium oxide. In some embodiments, the nanoporous substrate is a nanoporous titanium metal alloy-containing substrate; in a non-limiting example, the nanoporous titanium metal alloy-containing substrate comprises Ti6A14V.Docket No. 2891.099AWO

[0016] In some embodiments, the plurality of nanotubes have a pore size of about 8 nm to about 150 nm, and / or a mean pore size of about 80 nm, and / or a length of about 1 nm to about 100 um, and / or a wall thickness of about 1 nm to about 53 nm, and / or a depth of about 1 nm to about 2130 nm, and / or an aspect ratio, defined as (nanotube long dimension / nanotube short dimension), of about 0.3 to about 5.

[0017] In some embodiments, the nanoporous substrate has a porosity of about 60% to about 80%.

[0018] In some embodiments, the nanoporous substrate has a surface energy of about 40 mJ / m2to about 60 mJ / m2In a non-limiting example, the nanoporous substrate has a surface energy of about 55 mJ / m2BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate embodiments of the disclosure and together with the detailed description herein, serve to explain the principles of the disclosure. It is emphasized that, in accordance with the standard practice in the industry, various features are not drawn to scale. In fact, the dimensions of the various features may be arbitrarily increased or reduced for clarity of discussion. The drawings are only for purposes of illustrating preferred embodiments and are not to be construed as limiting the disclosure.

[0020] FIG. 1 shows a non-limiting example of scanning electron microscopy (SEM) images of nanoporous magnesium oxide, in accordance with an aspect of the present disclosure;

[0021] FIG. 2 shows an example schematic depicting a complement fixation assay, in accordance with an aspect of the present disclosure;

[0022] FIG. 3 shows a non-limiting example of complement activation assay data for magnesium oxide substrates, in accordance with an aspect of the present disclosure;

[0023] FIG. 4 shows an example schematic depicting a complement-mediated cell lysis assay, in accordance with an aspect of the present disclosure;

[0024] FIG. 5 shows a non-limiting example of complement-mediated cell lysis assay data, in accordance with an aspect of the present disclosure;

[0025] FIG. 6 shows a non-limiting example of comparative bacterial colonization data, in accordance with an aspect of the present disclosure;Docket No. 2891.099AWO

[0026] FIG. 7 shows a non-limiting example of comparative bacterial inhibition data, in accordance with an aspect of the present disclosure;

[0027] FIG. 8 shows a non-limiting example of comparative MRSA inhibition data of sample supernatants, in accordance with an aspect of the present disclosure;

[0028] FIG. 9 shows a non-limiting example of comparative MRSA inhibition data, in accordance with an aspect of the present disclosure;

[0029] FIG. 10 shows a non-limiting example of comparative osteoblast adhesion data, in accordance with an aspect of the present disclosure;

[0030] FIG. 11 shows a non-limiting example of comparative osteoblast mineralization data, in accordance with an aspect of the present disclosure.

[0031] FIG. 12 shows a non-limiting example of comparative bacterial inhibition data per anodized Ti6A14V nanotube wall thickness, in accordance with an aspect of the present disclosure;

[0032] FIG. 13 shows a non-limiting example of comparative bacterial inhibition data per anodized Ti6A14V nanotube depth, in accordance with an aspect of the present disclosure;

[0033] FIG. 14 shows a non-limiting example of comparative bacterial inhibition data per anodized Ti6A14V nanotube aspect ratio (i.e., nanotube long dimension / nanotube short dimension), in accordance with an aspect of the present disclosure;

[0034] FIG. 15 shows a non-limiting example of comparative osteoblast adhesion data per anodized Ti6A14V nanotube wall thickness, in accordance with an aspect of the present disclosure;

[0035] FIG. 16 shows a non-limiting example of comparative osteoblast adhesion data per anodized Ti6A14V nanotube depth, in accordance with an aspect of the present disclosure; and

[0036] FIG. 17 shows a non-limiting example of comparative osteoblast adhesion data per anodized Ti6A14V nanotube aspect ratio (nanotube long dimension / nanotube short dimension), in accordance with an aspect of the present disclosure.Docket No. 2891.099AWODETAILED DESCRIPTION

[0037] Orthopedic implants are often used to correct skeletal injury that require surgically installed fixation hardware to support bones through healing. Non-permanent, biodegradable implants are desirable as they eliminate the need for secondary surgeries. Because magnesium exists naturally in human bone, it can serve as a biocompatible, osteoconductive, biodegradable implant material. However, as a magnesium-based implant biodegrades, it may generate degradation products that can be toxic. Magnesium-based implants typically degrade via the corrosion reaction Mg + 2H2O — Mg(0H)2 + H2. Thus, one product generated from the biodegradation of magnesium-based implants is hydrogen (H2) gas, which can be harmful to cells, tissues, or organs in close proximity to the implant site or systemically. Formation of hydrogen gas can cause local hydrogen saturation of tissues and blood, hindering diffusion and solubility of hydrogen ions, and increasing the acidity of the blood. The body may respond to the corrosion reaction products released by the metal implant and produce a variety of biological responses.

[0038] In addition to the harmful products that can be released when an implant biodegrades, implanted medical devices are challenged by a foreign body response, beginning first with surgical wound trauma followed by localized activation of the clotting cascade. A subsequent influx of immune cells from the blood and lymphatic systems leads to an escalation of cytokine and proinflammatory proteins ending with fibrotic scarring or “walling off’ of the device at the implant site. Each phase of the response involves a complex array of triggers over time. None of these responses benefit the functionality of the therapeutic implant.Dampening or blocking any aspect of the whole foreign body response is an asset to improving device efficacy.

[0039] Molecular activation of the complement cascade is a significant risk in the initial stages after device implantation. Complement is a system of proteins ubiquitously present in plasma and tissue that promotes an inflammatory and immune defense reaction. Complement activation or fixation is a rapid response to foreign materials, including medical devices having blood or lymph contact. In certain cases, inherent properties of the material, for example surface texture, charge, free amine, or hydroxyl groups, can start the activation process. The activation process follows a sequential series of binding and enzymatic cleavage steps of different complement proteins to generate and release new molecular entities, many of which are pro-inflammatory. For example, complement activation can result in cell lysis. Activation by these processes may follow one of two cascades, referred to as the Classical orDocket No. 2891.099AWOAlternative Pathways. Complement activation contributes to localized inflammation and exacerbation of fibrosis (foreign body response).

[0040] The present disclosure addresses disadvantages of current magnesium-based implants through the provision of an anodized, nanoporous magnesium oxide substrate for use as a biodegradable implant, and a method for producing the same. The present disclosure overcomes problems existing in the art, for example, by reducing H2 gas formation caused by magnesium-based implant biodegradation, decreasing complement activation, and inhibiting complement-mediated cell lysis.

[0041] Non-limiting examples of magnesium-based substrates in accordance with the present disclosure may include magnesium oxide substrates, magnesium oxide films, magnesium oxide thin films, magnesium oxide coatings or layers for medical devices or medical implants, or medical devices or medical implants comprising magnesium oxide, or other magnesium-containing materials. In some embodiments, pure magnesium and magnesium-based particles, or magnesium and magnesium-based wires may also be employed.

[0042] Additionally, a nanoporous substrate can be made by anodizing metals or metal alloys to produce nanopores of different geometries, which have various properties, such as cytocompatibility. The present disclosure provides for an engineered nanoporous titanium metal alloy-based implant having anodized pores of specific geometries to control a biological response. Anon-limiting example of a titanium metal alloy -based substrate is Ti6A14V. Non-limiting examples of substrates include commercially available pure titanium (Ti), beta-type titanium alloys (e.g., Ti-13Nb-13Zr, Ti-29Nb-13Ta-4.6Zr, and the like known to persons of skill in the art), Nitinol, stainless steel, CoCrMo, and any metal that oxidizes, as would be known to persons of skill in the art.

[0043] Substrates in accordance with the present disclosure may have a varying degree of porosity. The porosity of a substrate is the percentage of void space in the substrate's structure. Thus, a substrate with 50% porosity has 50% void space in the structure of the substrate. Porous substrates may be used as implants to improve bone healing and fixation. Implants comprising porous substrates may be beneficial for subjects with compromised bone quality. The porosity of an implant can affect its biodegradation rate, infection, inflammation, corrosion, mechanical properties, and osteoconductivity.

[0044] The substrate may have a porosity in the range of about 60% to about 80%, including all ranges, subranges, and values therein, e.g., about 60% to about 65%, about 65% to aboutDocket No. 2891.099AWO70%, about 70% to about 75%, about 75% to about 80%, about 60% to about 70%, about 70% to about 80%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%.

[0045] The pore size of the substrate can affect certain biocompatibility characteristics. For example, implants comprising a nanoporous magnesium-based substrate may be particularly beneficial for reducing complement activation and hydrogen gas formation caused by the biodegradation magnesium-based implants.

[0046] The nanoporous substrate may have a pore size ranging from about 8 nm to about 100 nm, including all ranges, subranges, and values therein. In some embodiments, the pore size can be about 8 nm, about 9 nm, about 10 nm, about 11 nm, about 12 nm, about 13 nm, about 14 nm, about 15 nm, about 16 nm, about 17 nm, about 18 nm, about 19 nm, about 20 nm, about 21 nm, about 22 nm, about 23 nm, about 24 nm, about 25 nm, about 26 nm, about 27 nm, about 28 nm, about 29 nm, about 30 nm, about 31 nm, about 32 nm, about 33 nm, about 34 nm, about 35 nm, about 36 nm, about 37 nm, about 38 nm, about 39 nm, about 40 nm, about 41 nm, about 42 nm, about 43 nm, about 44 nm, about 45 nm, about 46 nm, about 47 nm, about 48 nm, about 49 nm, about 50 nm, about 51 nm, about 52 nm, about 53 nm, about 54 nm, about 55 nm, about 56 nm, about 57 nm, about 58 nm, about 59 nm, about 60 nm, about 61 nm, about 62 nm, about 63 nm, about 64 nm, about 65 nm, about 66 nm, about 67 nm, about 68 nm, about 69 nm, about 70 nm, about 71 nm, about 72 nm, about 73 nm, about 74 nm, about 75 nm, about 76 nm, about 77 nm, about 78 nm, about 79 nm, about 80 nm, about 81 nm, about 82 nm, about 83 nm, about 84 nm, about 85 nm, about 86 nm, about 87 nm, about 88 nm, about 89 nm, about 90 nm, about 91 nm, about 92 nm, about 93 nm, about 94 nm, about 95 nm, about 95 nm, about 97 nm, about 98 nm, about 99 nm, about 100 nm, about 105 nm, about 110 nm, about 115 nm, about 120 nm, about 125 nm, about 130 nm, about 135 nm, about 140 nm, about 145 nm, or about 150 nm.

[0047] The nanoporous substrate may have an average pore size of about 70 nm to about 90 nm, including all ranges, subranges, and values, therein. In some embodiments, the nanoporous substrate may have an average pore size of about 70 nm, about 71 nm, about 72 nm, about 73 nm, about 74 nm, about 75 nm, about 76 nm, about 77 nm, about 78 nm, about 79 nm, about 80 nm, about 81 nm, about 82 nm, about 83 nm, about 84 nm, about 85 nm, about 86 nm, about 87 nm, about 88 nm, about 89 nm, or about 90 nm.Docket No. 2891.099AWO

[0048] In some embodiments, the nanoporous substrate comprises nanotubes. The length of the nanotubes of the magnesium-based implant can affect the release of hydrogen gas from the site at which the implant biodegrades. The nanotubes can have a length of about 1 nm to about 100 pm. In some embodiments, the nanotubes can have a length of about 1 nm, about 2 nm, about 3 nm, about 4 nm, about 5 nm, about 6 nm, about 7 nm, about 8 nm, about 9 nm, about 10 nm, about 15 nm, about 20 nm, about 25 nm, about 30 nm, about 35 nm, about 40 nm, about 45 nm, about 50 nm, about 55 nm, about 60 nm, about 65 nm, about 70 nm, about 75 nm, about 80 nm, about 85 nm, about 90 nm, about 95 nm, about 100 nm, about 110 nm, about 120 nm, about 130 nm, about 140 nm, about 150 nm, about 160 nm, about 170 nm, about 180 nm, about 190 nm, about 200 nm, about 220 nm, about 240 nm, about 260 nm, about 280 nm, about 300 nm, about 320 nm, about 340 nm, about 360 nm, about 380 nm, about 400 nm, about 420 nm, about 440 nm, about 460 nm, about 480 nm, about 500 nm, about 520 nm, about 540 nm, about 560 nm, about 580 nm, about 600 nm, about 620 nm, about 640 nm, about 660 nm, about 680 nm, about 700 nm, about 720 nm, about 740 nm, about 760 nm, about 780 nm, about 800 nm, about 820 nm, about 840 nm, about 860 nm, about 880 nm, about 900 nm, about 920 nm, about 940 nm, about 960 nm, about 980 nm, about 1 pm, about 2 pm, about 3 pm, about 4 pm, about 5 pm, about 6 pm, about 7 pm, about 8 pm, about 9 pm, about 10 pm, about 15 pm, about 20 pm, about 25 pm, about 30 pm, about 35 pm, about 40 pm, about 45 pm, about 50 pm, about 65 pm, about 70 pm, about 75 pm, about 80 pm, about 85 pm, about 90 pm, about 95 pm, or about 100 pm.

[0049] In some embodiments, the nanotubes may have a wall thickness in the range of about 1 nm to about 53 nm, including all ranges, subranges, and values therein. Non-limiting examples of nanotube wall thickness include 5 nm, 15 nm, 35 nm, and 53 nm.

[0050] In some embodiments, the nanotubes may have a depth in the range of about 1 nm to about 2130 nm, including all ranges, subranges, and values therein. Non-limiting examples of nanotube depth include 320 nm, 550 nm, 730 nm, 920 nm, 1055 nm, 1450 nm, and 2130 nm.

[0051] In some embodiments, the nanotubes may have an aspect ratio (i.e., nanotube long dimension / nanotube short dimension) in the range of about 0.3 to about 5, including all ranges, subranges, and values therein. Non-limiting examples of aspect ratios include 0.3, 0.7, 1.0, 1.1, 1.4, 3.0, and 5.0.

[0052] The substrate can have a surface energy of about 40 milli Joule per square meter (mJ / m2) to about 60 mJ / m2, including all ranges, subranges, and values therein. In someDocket No. 2891.099AWOembodiments, the surface energy of the substrate is about 40 mJ / m2, about 41 mJ / m2, about 42 mJ / m2, about 43 mJ / m2, about 44 mJ / m2, about 45 mJ / m2, about 46 mJ / m2, about 47 mJ / m2, about 48 mJ / m2, about 49 mJ / m2, about 50 mJ / m2, about 51 mJ / m2, about 52 mJ / m2, about 53 mJ / m2, about 54 mJ / m2, about 55 mJ / m2, about 56 mJ / m2, about 57 mJ / m2, about 58 mJ / m2, about 59 mJ / m2or about 60 mJ / m2

[0053] A method for producing a nanoporous magnesium oxide substrate is provided herein. The method may include placing a magnesium oxide substrate in an acidic solution; covering the magnesium oxide substrate in the acidic solution; and applying a voltage to the magnesium oxide substrate, thereby obtaining the nanoporous magnesium oxide substrate. In some embodiments, the nanoporous magnesium oxide substrate may be a medical device. In some embodiments, the method may include placing a pure magnesium, a magnesium-based substrate, or magnesium alloys in an acidic solution.

[0054] A method for producing a nanoporous Ti6A14V substrate is provided herein. The method may include placing a Ti6A14V substrate in acidic solution; covering the Ti6A14V substrate in the acidic solution; and applying a voltage to the Ti6A14V substrate, thereby obtaining the nanoporous Ti6A14V substrate.

[0055] In some embodiments, the substrate may have a thickness of about 10 microns.

[0056] In some embodiments, the substrate is placed in an acidic solution. In some embodiments, the acidic solution comprises a fluoride-containing acid. In some embodiments, the acidic solution is hydrofluoric acid or fluoroantimonic acid. For example, the acidic solution may comprise 1.5% hydrofluoric acid.

[0057] The substrate may be covered with an acidic solution for about 1 minute to about 60 minutes, including all ranges, subranges, and values therein. In some embodiments, the substrate is covered with an acidic solution for 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 21 minutes, 22 minutes, 23 minutes, 24 minutes, 25 minutes, 26 minutes, 27 minutes, 28 minutes, 29 minutes, 30 minutes, 31 minutes, 32 minutes, 33 minutes, 34 minutes, 35 minutes, 36 minutes, 37 minutes, 38 minutes, 40 minutes, 41 minutes, 42 minutes, 43 minutes, 44 minutes, 45 minutes, 46 minutes, 47 minutes, 48 minutes, 49 minutes, 50 minutes, 51 minutes, 52 minutes, 53 minutes, 54 minutes, 55 minutes, 56 minutes, 57 minutes, 58 minutes, 59 minutes, or 60 minutes.Docket No. 2891.099AWO

[0058] The voltage may be applied to the substrate at about 1 volt to about 25 volts, including all ranges, subranges, and values therein. In some embodiments, the voltage applied to the substrate may be from about 1 volt to about 5 volts, about 5 volts to about 10 volts, about 10 volts to about 15 volts, about 15 volts to about 20 volts, about 20 volts to about 25 volts, about 1 volt to about 10 volts, about 5 volts to about 15 volts, about 10 volts to about 20 volts, about 15 volts to about 25 volts, etc. In some embodiments, the voltage applied to the substrate may be about 1 volt, about 2 volts, about 3 volts, about 4 volts, about 5 volts, about 6 volts, about 7 volts, about 8 volts, about 9 volts, about 10 volts, about 11 volts, about 12 volts, about 13 volts, about 14 volts, about 15 volts, about 16 volts, about 17 volts, about 18 volts, about 19 volts, about 20 volts, about 21 volts, about 22 volts, about 23 volts, about 24 volts, or about 25 volts.

[0059] In some embodiments, the application of the voltage to the substrate anodizes the substrate. In some embodiments, anodization of the substrate produces nanotubes in the substrate. For example, applying a voltage to a magnesium oxide substrate produces nanotubes, and the nanotubes may result in more effective release of H2 gas when the magnesium-based implant biodegrades. In some embodiments, anodization of the substrate does not produce nanotubes.

[0060] In some embodiments, the substrate is a metal -containing substrate other than a magnesium-containing substrate. For example, the metal-containing substrate may include a metal commonly used in orthopedics and medical devices, such as Ti6A14V. In some embodiments, the above features can be used to control anodized nanopore geometries (such as nanopore wall thickness, nanotube depth, nanotube aspect ratio, etc.) to decrease harmful bacteria colonization, thereby decreasing orthopedic implant failure. Similarly, the above features can be used to control anodized nanopore geometries to increase osteoblast function, thereby increasing orthopedic implant success.EXAMPLES

[0061] The following examples are intended to illustrate particular embodiments of the present disclosure but are by no means intended to limit the scope thereof.

[0062] Although some non-limiting examples have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, and the like can be made without departing from the spirit of theDocket No. 2891.099AWOpresent disclosure and these are therefore considered to be within the scope of the present disclosure as defined in the claims that follow.

[0063] It should be appreciated that all combinations of the foregoing concepts and additional concepts discussed in greater detail herein (provided such concepts are not mutually inconsistent) are contemplated as being part of the inventive subject matter disclosed herein. In particular, all combinations of claimed subject matter appearing at the end of this disclosure are contemplated as being part of the inventive subject matter disclosed herein and may be used to achieve the benefits and advantages described herein.

[0064] As used herein, the term “about” means that the numerical value is approximate, and small variations would not significantly affect the practice of the disclosed embodiments. Where a numerical limitation is used, unless indicated otherwise by the context, “about” means the numerical value can vary by ±1 or ±10% , or any point therein, and remain within the scope of the disclosed embodiments.

[0065] Example: Nanoporous Magnesium Oxide Substrate

[0066] FIG. 1 shows a non-limiting example of scanning electron microscopy (SEM) top view and cross-sectional images of magnesium oxide thin films. In some embodiments, the magnesium oxide thin films are 10 microns (pm) thick. The magnesium oxide thin films were placed in 1.5% hydrofluoric acid for 15 minutes and exposed to 20 volts (V). The magnesium oxide samples were then visualized under scanning electron microscopy (SEM) where a through nanoporous structure was created.

[0067] Anon-limiting example of porosity characteristics data of the magnesium oxide samples of FIG. 1 is shown in Table 1, below. Using standard gas adsorption porosimetry methods, the magnesium oxide samples of FIG. 1 were characterized for porosity immediately after fabrication (i.e., 0 Days) and after seven days of soaking in cell culture media under standard incubator conditions (i.e., 7 Days). In some embodiments, the cell media culture comprised Dulbecco's Modified Eagle Media (DMEM) and 10% fetal bovine serum (FBS). Example standard incubator conditions include a temperature of 37°C and air / CCh ratio of 95 / 5%. The data in Table 1 confirms that the nanoporosity of the magnesium oxide samples was stable for the duration of the seven (7) days.Table 1Docket No. 2891.099AWOMin Pore Mean Pore Max PoreSample % PorositySize (nm) Size (nm) Size (nm)Control MgO 0 0 0 0MgO Nanopores 9.2 80.0 95.1 71.0 0 Days MgO975.2 1025.5 1250.3 69.7 microporesControl MgO 0 0 0 0MgO Nanopores 9.9 79.8 96.1 71.2 7 Days MgO965.1 1029.0 1233.3 71.4micropores

[0068] A non-limiting example of surface energy and chemical composition measurements of the magnesium oxide samples of FIG. 1 is shown in Table 2, below. The surface energy and chemical composition of the through-nanoporous magnesium oxide membranes of FIG. 1 was measured using energy dispersive spectroscopy. Measurements were taken both immediately after the nanoporous magnesium oxide was synthesized and seven days after culture in cell culture media, and in an incubator under standard incubator conditions. At both time points, the data confirmed the presence of magnesium oxide of higher surface energy when possessing through nanoporous magnesium oxide.Table 2Surface EnergySample % Mg % O(mJ / m2)Control MgO 14.95 52 480MgO Nanopores 55.4 51 49DaysMgO micropores 32.3 51 49Control MgO 15.01 51 497MgO Nanopores 54.9 52 48DaysMgO micropores 34.2 52 48Docket No. 2891.099AWO

[0069] One of the largest disadvantages of using biodegradable magnesium oxide as an implant is that it generates H2 gas during degradation. Thus, H2 gas formation was evaluated after soaking the non-anodized magnesium implant and the through nanoporous magnesium implant in cell culture media for up to 28 days. H2 gas formation was assessed using pH measurements, where lower pH values correspond to increased H2 gas formation. Table 3, below, shows a non-limiting example of pH change data for the cell culture media containing magnesium oxide samples of varying porosity across 1, 7, 21, and 28 days. Results showed significantly less pH change, and thus less H2 gas formation, using the magnesium oxide samples comprising through nanopores, when compared to the control, non-porous magnesium oxide and micropore-containing magnesium oxide.Table 3Sample 1 Day 7 Days 21 Days 28 DaysControl MgO 7.3 2.4 1.2 1MgO Nanopores 7.4 7.4 7.4 7.1MgO micropores 7.4 6.1 3.9 1.1

[0070] FIG. 2 outlines an example schematic for a complement activation assay assessing the presence of C3b and C5b cleavage products and fixation (i.e., respective protein adsorption) to the material. In the first step of the assay method depicted in FIG. 2, a substrate is immersed in a mixture of serum and complement proteins and incubated for one hour to allow for binding and activation of the complement proteins. Next, the substrate is washed extensively to remove residual unbound proteins. Then, complement proteins bound to the substrate can be detected and quantified using fluorescent tags capable of binding to C3b and C5b.

[0071] FIG. 3 shows a non-limiting example of representative data from the complement activation assay depicted in FIG. 2. The graph compares the relative amount of complement proteins fixed to a control, non-porous magnesium oxide substrate with the relative amount of complement proteins fixed to nanoporous magnesium oxide comprising 80 nanometer pores. Relative fixation of complement proteins C3b is shown in blue, and relative fixation of complement proteins C5b is shown in orange. Relative amounts of bound complement proteins correspond to relative quantifications of immunofluorescent signal, as described inDocket No. 2891.099AWOFIG. 2. The data demonstrate that complement activation is significantly reduced on the anodized, through nanoporous magnesium oxide when compared to non-porous, control magnesium oxide substrate.

[0072] The presence and function of complement enzymatic activation can be quantified by the lysis of cells. FIG. 4 outlines an example schematic depicting a representative assay to measure complement diffusion and lysis. The metal substrate sample coupon is placed in a test fixture and exposed to a source of serum and complement proteins in the top chamber to allow lytic complement derivatives to form. Then, the sample is further incubated to permit diffusion of lytic complement derivatives through the membrane pores to reach a source of red cells on the opposing side. Cell lysis is measured by the release of heme from ruptured cells into the assay supernatant, quantified by spectrophotometric analysis.

[0073] FIG. 5. shows a non-limiting example of representative results of the assay depicted in FIG. 4. The data indicate that no red blood cell lysis was observed for the magnesium oxide substrate comprising 80 nm pores, when compared to the control, non-porous magnesium oxide substrate, in which a higher magnitude of red blood cell lysis was observed.

[0074] Infection and bacterial colonization are risks associated with some biomedical implants. In order to assess the bacterial colonization on magnesium-based substrates in accordance with the present disclosure, a selection of Gram positive (G+) and Gram negative (G-) bacteria were chosen. For example, S. mutans (Sm, UA159, G+), Porphyromonas gingivalis (Pg, ATCC33277, G-), Fusobacterium nucleatum (Fn, ATCC25586, G-), Methicillin-resistant Staphylococcus aureus (MRSA) (ATCC 43300, G+), Methicillin-resistant Staph, epidermidis (MRSE) (ATCC 14990), Pseudomonas aeruginosa (ATCC 10145, G+), and Escherichia coli (G-) were inoculated (106colony forming units / sample) on the proposed surfaces (the proposed surface being either tissue culture plastic surface (TCPS), non-anodized magnesium oxide substrate, or a nanoporous magnesium oxide substrate) for 24, 48, and 72 hours. The dry pellet was rehydrated in 6 mL of Luria broth (LB) consisting of 10 grams (g) tryptone, 5g yeast extract, and 5g sodium chloride (NaCl) per liter double distilled water with the pH adjusted to 7.4 (all chemicals obtained from Sigma Aldrich, St. Louis, MO, USA). 10% fetal bovine serum (FBS; Hyclone) was added to the LB to more accurately represent real body fluid. The bacteria solution was agitated under standard cell conditions (5% CO2 / 95% humidified air at 37°C) for 24 hours until the stationary phase was reached. The second passage of bacteria was diluted at a ratio of 1 :200Docket No. 2891.099AWOinto fresh LB supplemented with 10% FBS and incubated until reaching the stationary phase. The second passage was then be frozen in one part LB and 10% FBS and one part glycerol (Sigma Aldrich) and stored at -18°C. All experiments were conducted from this frozen stock. One day before bacterial seeding for experiments, a sterile 10 pl loop was used to withdraw bacteria from the frozen stock and to inoculate a centrifuge tube with 3 mL of fresh LB supplemented with 10% FBS. At the end of 24, 48, and 72 hours, standard colony forming units were determined using the spreading and plating method.

[0075] As shown in FIG. 6, a 3-4 log reduction in colonization of each bacterial strain on anodized magnesium oxide substrates was observed when compared to TCPS and nonanodized MgO substrates.

[0076] Furthermore, to evaluate the antibacterial activity of the nanoporous magnesium substrates, MRSA were incubated in 3.7% brain heart infusion (BHI) broth solution under standard anaerobic conditions (80% N2, 10% H2, 10% CO2, 37 °C). After being cultured with the bacterial suspension for 24 h, 48 h, and 72 h, each sample (20 mm x 20 mm x 1 mm) was put into a centrifuge tube with 10 mL BHI and then will be vibrated using a Vortex Genie 2 (3000 rpm, 1 min) before ultrasonically oscillated (50 Hz, 5 min) to dissociate the bacteria. After centrifugation for 10 min, the resuspended bacterial suspension was serially diluted with BHI, and 100 mL of the suspension was seeded onto an agar plate for further incubation. The number of active bacteria colony forming units (CFUs) will be counted using an automatic colony counter, and the antibacterial ratio was calculated.

[0077] As indicated in FIG. 7, a 3 log reduction in bacterial (MRSA) activity was shown on anodized magnesium oxide having a pore size of 20 nm and 150 nm, and a 4 log reduction in bacterial (MRSA) activity was shown on anodized magnesium oxide having a pore size of 80 nm, when compared to TCPS and non-anodized magnesium oxide control substrates.

[0078] FIG. 8 shows a non-limiting example of comparative MRSA inhibition data of sample supernatants. As shown in FIG. 8, a 3 log reduction in bacterial (MRSA) activity was shown for the supernatants of anodized magnesium oxide substrates having a pore size of 20 nm and 80 nm, and a 2 log reduction in bacterial (MRSA) activity was shown on the supernatants of anodized magnesium oxide substrates having a pore size of 150 nm, when compared to TCPS and non-anodized magnesium oxide control substrates.Docket No. 2891.099AWO

[0079] Direct kill-off assays were performed and antibacterial activity evaluated in accordance with the protocol outlined in “Plastics - Measurement of antibacterial activity on plastics surfaces” (ISO 22196 AM), the contents of which are appended hereto.

[0080] All cell experiments were run in triplicate and repeated a minimum of three times per substrate type. Numerical data will be analyzed using Analysis of Variance (ANOVA); values of p < 0.05 will be considered significant. Duncan’s multiple range tests will be used to determine differences between means.

[0081] As evidenced by FIG. 9, a 3 log reduction (i.e., kill-off) in MRSA was observed for anodized magnesium oxide substrates having a pore size of 80 nm across all three time points (1 day, 7 days, 14 days), when compared to TCPS and non-anodized magnesium oxide control substrates.

[0082] To further assess osteoblast adhesion, 3,500 human fetal osteoblasts (hFOB, ATCC CRL-11372) cells / ml media suspension were placed onto each sample (each sample being either a non-porous magnesium oxide substrate, non-anodized magnesium oxide substrate, or a nanoporous magnesium oxide substrate) in cell culture plates in DMEM plus 10% fetal bovine serum and 1% of penicillin-streptomycin. All plates were incubated in a humidified environment under 5% CO2 and 37 °C for 4 hours. At the completion of the incubation time, the samples were carefully transferred to new plates and immersed in a 16.7% v / v MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; Promega] solution (1 ml MTS : 5 ml DMEM-F12). Test specimens in MTS were incubated in a humidified atmosphere at 5% CO2 and 37 °C. After reduction of the tetrazolium compound, the bulk solutions surrounding each test specimen were re-suspended through continuous pipetting to ensure homogeneity in color saturation, and 200 pl from each solution were deposited into the wells of clear bottom 96-well plates. Absorbance readings at 1 equal to 490 nm were immediately obtained using a spectrophotometer. All procedures involving MTS were performed in the dark to avoid the discoloration of the reagent due to light-sensitivity. MTS procedures were performed on three replicates of each sample type.

[0083] All cell experiments were run in triplicate and repeated a minimum of three times per substrate type. Numerical data was analyzed using Analysis of Variance (ANOVA); values of p < 0.05 were considered significant. Duncan’s multiple range tests were used to determine differences between means.Docket No. 2891.099AWO

[0084] As shown in FIG. 10, osteoblast adhesion was enhanced on anodized, nanoporous magnesium oxide substrates when compared to non-anodized magnesium oxide or TCPS controls. In particular, anodized, nanoporous magnesium oxide substrates having average pore sizes of 20 nm, 80 nm, and 150 nm all demonstrated equally improved osteoblast adhesion when compared to control substrates.

[0085] Mineralization, or calcium deposition, by osteoblasts is a critical function in new bone formation. To assess osteoblast mineralization and calcium deposition, 40,000 hFOB cells / ml cultured under normal conditions (5% CO2 and 37 °C) were placed onto the samples (each sample being either a non-porous magnesium oxide substrate, non-anodized magnesium oxide substrate, or a nanoporous magnesium oxide substrate) in DMEM supplemented with 10% of fetal bovine serum and 1% of penicillin-streptomycin for 7, 14 and 21 days. Cell culture media was carefully replaced every 72 hours under sterile conditions. At the end of the prescribed time period, the substrates were transferred into cell culture plates using a sterile tweezer. To avoid the mechanical disengagement of deposited calcium during the solvent exchanges or washes, care was practiced to carefully remove and re-introduce any liquid media. The plates were tilted slightly, and solvent additions will be performed dropwise along the walls of the 48-well plates, crosswise and away from the samples. After the samples were washed with phosphate-buffered saline (PBS), 0.50 ml of a 0.60 M HC1 solution was added to the experimental wells in order to promote calcium dissolution and decalcification. All plates were maintained for 4 hours at room temperature on a platform shaker set to 115 revolutions per minute (rpm). After shaking, the contents of each well containing test samples were transferred to 1 ml Eppendorf tubes and centrifuged at 12,000 rpm for 3 min. The calcium content in the HC1 supernatants was determined with the aid of the QuantiChrom Calcium Assay Kit (BioAssay Systems). 5 pl of each sample and 200 pl of a calcium detecting working reagent containing phenolsulphonephthalein dye was mixed inside of clear bottom 96-well plates and incubated at room temperature for 3 min.Spectrophotometric readings were taken at a equal to 612 nm, and calcium concentrations were determined by fitting data to a calibration curve prepared using 20 mg / dL Ca2+calcium standards. The mineralization data was determined for three replicates each repeated three times.

[0086] All cell experiments were run in triplicate and repeated a minimum of three times per substrate type. Numerical data was analyzed using Analysis of Variance (ANOVA); values ofDocket No. 2891.099AWOp < 0.05 were considered significant. Duncan’s multiple range tests were used to determine differences between the means.

[0087] As shown in FIG. 11, all three anodized, nanoporous magnesium oxide substrates (i.e., nanoporous magnesium oxide substrates having average pore sizes of 20 nm, 80 nm, and 150 nm) showed greater osteoblast mineralization when compared to control substrates, across all three time points.

[0088] In some embodiments, magnesium substrates in accordance with the present disclosure can be used to complement other approaches to inhibit bacteria, limit inflammation, and promote tissue growth.

[0089] In further embodiments of the invention the nanoporous magnesium substrate can be implanted with other antibacterial and / or antimicrobial components. For example, the nanoporous substrate can be implanted with magnesium ions. Magnesium ions can elute from the surface and have some ability to inhibit bacteria. In non-limiting examples of the present disclosure, the magnesium ions may show an ability to reduce bacterial colonies by 5-10 % compared to a control.

[0090] Example: Nanoporous Ti6A14V Substrate

[0091] To obtain nanoporous Ti6A14V substrates having a nanotube wall thickness of 5 nm, 15 nm, 35 nm, or 53 nm, and / or a nanotube depth of 320 nm, 550 nm, 730 nm, 920 nm, 1055 nm, 1450 nm, or 2130 nm, and / or a nanotube aspect ratio of 0.3, 0.7, 1.0, 1.1, 1.4, 3.0, or 5.0, Ti6A14V substrates were placed in 0.5 - 1.5% hydrofluoric acid for about 5 to about 25 minutes and exposed to about 10 to about 20 volts.

[0092] For example, nanoporous Ti6A14V substrates were made under the following conditions to achieve the following nanotube wall thickness (Table 4), nanotube depth (Table 5), or nanotube aspect ratio (Table 6).Table 4Nanotube Wall Hydrofluoric Time VoltageThickness (nm) Acid (wt.%) (minutes) (V)5 0.5 5 1015 0.9 10 15Docket No. 2891.099AWO35 1.2 15 1553 1.5 25 20Table 5Nanotube Depth Hydrofluoric Time Voltage(nm) Acid (wt.%) (minutes) (V)320 0.5 5 10550 0.5 10 15730 1 10 15920 1 15 201055 1 20 201450 1.5 20 252130 1.5 25 25Table 6Nanotube Aspect Hydrofluoric Time VoltageRatio Acid (wt.%) (minutes) (V)0.3 0.5 5 100.7 0.7 7 131.0 0.9 9 161.1 1.1 11 191.4 1.3 13 223.0 1.5 20 225.0 1.5 25 25

[0093] To evaluate the antibacterial activity of the nanoporous Ti6A14V substrates, MRSA were incubated in 3.7% brain heart infusion (BHI) broth solution under standard anaerobic conditions (80% N2, 10% H2, 10% CO2, 37 °C). After being cultured with the bacterialDocket No. 2891.099AWOsuspension for 24 h, each sample (20 mm x 20 mm x 1 mm) was put into a centrifuge tube with 10 mL BHI and was vibrated using a Vortex Genie 2 (3000 rpm, 1 min) before being ultrasonically oscillated (50 Hz, 5 min) to dissociate the bacteria. After centrifugation for 10 min, the resuspended bacterial suspension was serially diluted with BHI, and 106CFU / sample was seeded onto an agar plate for further incubation. The number of active bacteria colony forming units (CFUs) were counted using an automatic colony counter, and the antibacterial ratio was calculated.

[0094] As shown in FIG. 12, MRS A colonization for 24 h was dependent on anodized nanotube wall thickness, with the lowest number of MRS A measured on nanoporous Ti6A14V substrates having a nanotube wall thickness of 5 nm.

[0095] As shown in FIG. 13, MRSA colonization for 24 h was dependent on anodized nanotube depth, with the lowest number of MRS A measured on nanoporous Ti6A14V substrates having a nanotube wall depth of 1055 nm.

[0096] As shown in FIG. 14, MRSA colonization for 24 h was dependent on anodized nanotube aspect ratio (i.e., nanotube long dimension / nanotube short dimension), with the lowest number of MRS A measured on nanoporous Ti6A14V substrates having a nanotube aspect ratio of 1.4 or 3.

[0097] To assess osteoblast adhesion, 3,500 human fetal osteoblasts (hFOB, ATCC CRL-11372) cells / ml media suspension were placed onto each sample (each sample being either a non-anodized Ti6A14V substrate, or a nanoporous Ti6A14V substrate with a nanotube wall thickness of 5 nm, 15 nm, 35 nm, or 53 nm) in cell culture plates in DMEM plus 10% fetal bovine serum and 1% of penicillin-streptomycin. All plates were incubated in a humidified environment under 5% CO2 and 37 °C for 4 hours. At the completion of the incubation time, the samples were carefully transferred to new plates and immersed in a 16.7% v / v MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; Promega] solution (1 ml MTS : 5 ml DMEM-F12). Test specimens in MTS were incubated in a humidified atmosphere at 5% CO2 and 37 °C. After reduction of the tetrazolium compound, the bulk solutions surrounding each test specimen were re-suspended through continuous pipetting to ensure homogeneity in color saturation, and 200 pl from each solution were deposited into the wells of clear bottom 96-well plates. Absorbance readings at 1 equal to 490 nm were immediately obtained using a spectrophotometer. All proceduresDocket No. 2891.099AWOinvolving MTS were performed in the dark to avoid the discoloration of the reagent due to light-sensitivity. MTS procedures were performed on three replicates of each sample type.

[0098] As shown in FIG. 15, osteoblast adhesion for 4 h was dependent on anodized nanotube wall thickness, with the greatest numbers of osteoblasts measured on nanoporous Ti6A14V substrates having a nanotube wall thickness of 5 nm.

[0099] As shown in FIG. 16, osteoblast adhesion for 4 h was dependent on anodized nanotube depth, with the greatest numbers of osteoblasts measured on nanoporous Ti6A14V substrates having a nanotube depth of 550 nm or 730 nm.

[0100] As shown in FIG. 17, osteoblast adhesion for 4 h was dependent on anodized nanotube aspect ratio (i.e., nanotube long dimension / nanotube short dimension), with the greatest number of osteoblasts measured on nanoporous Ti6A14V substrates having an aspect ratio of 0.3 or 0.7.

[0101] Example: Nanoporous Substrate - Macrophage Adhesion and Proliferation

[0102] In order to assess macrophage adhesion and proliferation, 3,500 macrophages (inflammatory cells; RAW.264.7. ATCC TIB-71) / mL media suspension will be placed onto each sample (for example, a non-porous magnesium oxide or titanium metal alloy substrate, a microporous magnesium oxide or titanium metal alloy substrate, or a nanoporous magnesium oxide or titanium metal alloy substrate) in cell culture plates in DMEM plus 10% fetal bovine serum and 1% of penicillin-streptomycin. All plates will then be incubated in a humidified environment under 5% CO2 and 37 °C for 1, 3, and 5 days. At the completion of the incubation time, the samples will be carefully transferred to new plates and immersed in a 16.7% v / v MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; Promega] solution (1 ml MTS : 5 ml DMEM-F12). Test specimens in MTS will be incubated in a humidified atmosphere at 5% CO2 and 37 °C. After reduction of the tetrazolium compound, the bulk solutions surrounding each test specimen will be re-suspended through continuous pipetting to ensure homogeneity in color saturation, and 200 pl from each solution will be deposited into the wells of clear bottom 96-well plates. Absorbance readings at 1 equal to 490 nm will be immediately obtained using a spectrophotometer. All procedures involving MTS will be performed in the dark to avoid the discoloration of the reagent due to light-sensitivity. MTS procedures will be performed on three replicates of each sample type.Docket No. 2891.099AWO

[0103] Cells will then be lysed by exposure to three freeze-thaw cycles and cell lysates collected and detected for interleukins (IL). Specifically, ELISA kits for pro-inflammatory interleukins IL-6, IL-8, and IL- 12, and anti-inflammatory proteins will be utilized to assess pro- versus anti-inflammatory behavior.

[0104] All cell experiments will be run in triplicate and repeated a minimum of three times per substrate type. Numerical data will be analyzed using Analysis of Variance (ANOVA); values of p < 0.05 will be considered significant. Duncan’s multiple range tests will be used to determine differences between means.

[0105] It is expected that macrophage adhesion, proliferation, and secretion of pro-inflammatory cytokines will decrease, while anti-inflammatory cytokines will increase, on nanotextured and nanotubular magnesium oxide or titanium metal alloy substrates.

[0106] Example: Nanoporous Substrate - Inflammatory Response and Function of Vascular Endothelial Cells

[0107] To evaluate the inflammatory response and function of vascular endothelial cells, vascular endothelial cells will be cultured by segregating rat bone marrow stromal cells (MSCs) from the femurs and tibiae of Sprague-Dawley (SD) rats (weight: 120-150 g). MSCs will be cultured with a-modified minimum essential medium (a-MEM) supplemented with 10% (v / v) fetal bovine serum (FBS, Hyclone, USA) and 1% (v / v) streptomycin / penicillin under atmosphere of 5% CO2 at 37 °C. Meanwhile, RAW264.7 and human umbilical vein endothelial cells (HUVECs) will be obtained. Both RAW264.7 cells and HUVECs will be cultured using DMEM medium with high glucose. Before cell culturing, all samples will be exposed to ultraviolet (UV)-irradiation overnight.

[0108] Next, confocal laser scanning microscopy (CLSM) will be used to observe the morphology of RAW264.7 cells on diverse specimens (for example, a non-porous magnesium oxide or titanium metal alloy substrate, a microporous magnesium oxide or titanium metal alloy substrate, or a nanoporous magnesium oxide or titanium metal alloy substrate).RAW264.7 cells at 2 * IO4cells / cm2will be cultured with different substrates for I day. Next, the specimens will be rinsed with warm PBS solution followed by fixing with PFA (v / v, 4%) at 4 °C overnight. Then, the cytoskeleton of RAW264.7 cells will be stained with Fluorescein Isothiocyanate (FITC)-phalloidin (Green) and the nucleus will be treated using blue Hoechst 33258, respectively. Lastly, CLSM will be used to observe the stained samples.Docket No. 2891.099AWOMeanwhile, RAW264.7 cells will be seeded on diverse specimens by the same approach as aforementioned. RAW264.7 cells will be cleaned using PBS buffer twice and incubated with 10 pg / mL of FDA / PI solution for 15 min under dark conditions. Lastly, the as-stained samples will be imaged with a fluorescence microscope (Zeiss, Jena, Germany). Next, CCK-8 assay will be performed to investigate the biocompatibility of native magnesium oxide samples. RAW264.7 cells will be cultured on different specimens by the same approach as aforementioned. The medium will be discarded followed by placing the specimens into another 24- well plate. 30 pL of CCK-8 solution and 270 pL fresh medium will be poured into each well with another 2 h of culture. Further, the mixture will be added to a new 96-well plate and the optical density (OD) value of the above mixture at OD450 will be measured by a spectrophotometric microplate reader (BioRad 680, USA). Lastly, real-time quantitative polymerase chain reaction (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA) will be used to investigate the inflammatory response. The total RNA of different samples will be collected from RAW264.7 cells by Trizol reagent and total RNA Extract Kit. The concentration of extracted RNA will be tested by NanoDrop (ThermoFisher Scientific, USA). Afterward, the first-strand complementary DNA (cDNA) will be obtained via reverse transcription. The expressions of inflammation-related genes of RAW 264.7 cells will be investigated by RT-qPCR, including inducible nitric oxide synthase (iNOS), tumor necrosis cluster of differentiation 86 (CD86), CDllc, CD206, Arginase-1 (Arg-1), and IL-10. The used primers (Sangon China) and the normalization of gene expression level against GADPH will be performed. For ELISA, RAW264.7 cells will be incubated with different specimens for 1 day. The supernatant of each sample will be harvested to assess the concentration of excretive cytokines in RAW264.7 cells, such as TNF-a, IL-6, IL-10, and TGF-p.

[0109] To assess endothelial cell adhesion, samples (for example, a non-porous magnesium oxide or titanium metal alloy substrate, a microporous magnesium oxide or titanium metal alloy substrate, or a nanoporous magnesium oxide or titanium metal alloy substrate) will be placed in a 24 well plate and sterilized with ultraviolet (UV) exposure overnight. A volume of 0.5 mL of endothelial cells (HUVEC, ECV304, 5 x 104cells / mL) suspension, and 1.5 mL of cell culture medium will be added into each well. The samples will be cultured at 37 °C and 5% CO2 for 1 or 3 days, respectively, and then washed three times by PBS. A volume of 200 pL of rhodamine (rhodamine-PBS = 1 :400) will be added on each sample surface for 20 min and then washed three times by PBS. Then, 200 pL of 4',6-diamidino-2-phenylindole (DAPI) (DAPI-PBS = 1 :400) will be added onto the sample surface to incubate for 3 min. TheDocket No. 2891.099AWOsample will be washed three times with PBS, and the cells will be observed by a fluorescent microscopy (Zeiss, inverted A2). At the same time, another parallel group of samples will be dehydrated by 50%, 70%, 90%, and 100% ethanol solutions for 10 min, respectively. After spraying a gold layer on the surface, the cell morphologies will be observed by scanning electron microscopy (SEM, FEI Quanta 250).

[0110] To assess endothelial cell proliferation, endothelial cells will be cultured with the samples (for example, a non-porous magnesium oxide or titanium metal alloy substrate, a microporous magnesium oxide or titanium metal alloy substrate, or a nanoporous magnesium oxide or titanium metal alloy substrate) in the same way. After cultured for 1 and 3 days, 0.5 mL of cck-8 solution (cck-8-cell culture medium = 9:1) will be added onto each sample, incubated 3.5 h at 37 °C. The absorbance will be measured by a microplate reader (Bio-Tek Eons) at 450 nm. Triplicate parallel samples will be measured, and the values will be averaged for each sample.

[0111] To examine nitric oxide (NO) secretion, the Griess method will be used to measure the NO amount released from the endothelial cells. Griess Reagent I and II will first be returned to room temperature, and the standard samples (for example, a non-porous magnesium oxide or titanium metal alloy substrate, a microporous magnesium oxide or titanium metal alloy substrate, or a nanoporous magnesium oxide or titanium metal alloy substrate) will be prepared at the same time. The endothelial cells will be cultured on the surface for 1 and 3 days. The endothelial cell culture supernatant will be pipetted, and a standard sample and a cell supernatant will be added into a 96-well plate. Griess Reagent I and II will in turn be added into the platelet well. The optical density (OD) value at 540 nm will be measured by a microplate reader, and the NO concentration will be calculated according to the standard curve.

[0112] To measure the vascular endothelial growth factor (VEGF) expression of endothelial cells, the enzyme-linked immunosorbent method will be used. First, the endothelial cells will be cultured on the sample surface (for example, a non-porous magnesium oxide or titanium metal alloy substrate, a microporous magnesium oxide or titanium metal alloy substrate, or a nanoporous magnesium oxide or titanium metal alloy substrate) for 1 and 3 days, and the supernatant will be extracted to dilute 5 times and then added into the enzyme plate. After incubating 30 min at 37 °C, 50 pL of enzyme standard reagent will be added into each well to culture 30 min at 37 °C. The sample will be washed five times repeatedly, 50 pL of chromogenic agent A and 50 pL of chromogenic agent B will be added to each well, and theDocket No. 2891.099AWOcolor will be developed in the dark for 10 min at 37 °C. Finally, the termination solution will be added to stop the reaction. The OD value at 450 nm will be measured by a microplate reader. The VEGF concentration will then be calculated according to the standard curve.

[0113] It is expected that vascular endothelial cells will exhibit improved function (including morphology, adhesion, proliferation, and synthesis of an extracellular matrix), increased nitric oxide expression, increased VEGF production, and increased migration on nanotextured and nanotubular substrates (for example, magnesium oxide substrates or titanium metal alloy substrates) while the synthesis of pro-inflammatory molecules will decrease.

[0114] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprise” (and any form of comprise, such as “comprises” and “comprising”), “have” (and any form of have, such as “has”, and “having”), “include” (and any form of include, such as “includes” and “including”), and “contain” (and any form of contain, such as “contains” and “containing”) are open-ended linking verbs. As a result, a method that “comprises,” “has,” “includes,” or “contains” one or more steps or elements possesses those one or more steps or elements, but is not limited to possessing only those one or more steps or elements. Likewise, a step of a method “comprises,” “has,” “includes,” or “contains” one or more features possesses those one or more features, but is not limited to possessing only those one or more features. Furthermore, a device or structure that is configured in a certain way is configured in at least that way, but may also be configured in ways that are not listed.

[0115] The disclosure has been described with reference to the preferred embodiments. It will be understood that the architectural and operational embodiments and methods described herein are exemplary of a plurality of possible arrangements to provide the same general features, characteristics, and general system or method operation. Modifications and alterations will occur to others upon a reading and understanding of the preceding detailed description. It is intended that the disclosure be construed as including all such modifications and alterations.

Claims

Docket No. 2891.099AWOCLAIMSWhat is claimed is:

1. A method comprising:providing a substrate, wherein the substrate is a magnesium-containing substrate or a titanium metal alloy-containing substrate;placing the substrate in an acidic solution;covering the substrate in the acidic solution; andapplying a voltage to the substrate, thereby producing a nanoporous substrate.

2. The method of claim 1, wherein the nanoporous substrate is a medical device.

3. The method of claim 1 or 2, wherein the substrate is a magnesium-containing substrate.

4. The method of claim 1 or 2, wherein the substrate is a titanium metal alloy-containing substrate.

5. The method of any one of claims 1-3, wherein the magnesium-containing substrate is magnesium oxide.

6. The method of any one of claims 1, 2, or 4, wherein the titanium metal alloycontaining substrate is Ti6A14V.

7. The method of any one of claims 1-6, wherein the nanoporous substrate comprises a plurality of nanotubes.Docket No. 2891.099AWO8. The method of claim 7, wherein the plurality of nanotubes have a wall thickness of about 1 nm to about 53 nm.

9. The method of claim 7, wherein the plurality of nanotubes have a depth of about 1 nm to about 2130 nm.

10. The method of claim 7, wherein the plurality of nanotubes have an aspect ratio of about 0.3 to about 5, wherein the aspect ratio is defined as nanotube long / short dimension.

11. The method of any one of claims 1-10, wherein the acidic solution comprises a fluoride-containing acid.

12. The method of any one of claims 1-11, wherein the acidic solution comprises hydrofluoric acid and / or fluoroantimonic acid.

13. The method of any one of claims 1-12, wherein the acidic solution comprises 1.5% hydrofluoric acid.

14. The method of any one of claims 1-13, wherein the voltage is in a range of about 1 volt to about 25 volts.

15. The method of any one of claims 1-14, wherein the voltage is 20 volts.

16. The method of any one of claims 1-15, wherein the substrate comprises a film, wherein the film has a thickness of 10 microns.

17. The method of any one of claims 1-16, wherein covering comprises covering the substrate in the acidic solution for about 1 minute to about 60 minutes.Docket No. 2891.099AWO18. The method of any one of claims 1-17, wherein covering comprises covering the substrate in the acidic solution for 15 minutes.

19. The method of claim 2, wherein the medical device is a medical implant.

20. The method of claim 2 or 19, wherein the medical device is biodegradable.

21. An implant, compri sing :a nanoporous substrate, wherein the nanoporous substrate comprises a plurality of nanotubes.

22. The implant of claim 21, wherein the nanoporous substrate is a nanoporous magnesium-containing substrate.

23. The implant of claim 22, wherein the nanoporous magnesium-containing substrate comprises magnesium oxide.

24. The implant of claim 23, wherein the nanoporous substrate is a nanoporous titanium metal alloy-containing substrate.

25. The implant of claim 24, wherein the nanoporous titanium metal alloy-containing substrate is Ti6A14V.

26. The implant of any one of claims 21-25, wherein the plurality of nanotubes has a pore size of about 8 nanometers to about 150 nanometers.Docket No. 2891.099AWO27. The implant of any one of claims 21-26, wherein the plurality of nanotubes has a mean pore size of about 80 nanometers.

28. The implant of any one of claims 21-27, wherein the plurality of nanotubes have a length of about 1 nanometer to about 100 microns.

29. The implant of any one of claims 21-28, wherein the plurality of nanotubes have a wall thickness of about 1 nm to about 53 nm.

30. The implant of any one of claims 21-29, wherein the plurality of nanotubes have a depth of about 1 mm to about 2130 nm.

31. The implant of any one of claims 21-30, wherein the plurality of nanotubes have an aspect ratio of about 0.3 to about 5, wherein the aspect ratio is defined as nanotube long / short dimension.

32. The implant of any one of claims 21-31, wherein the nanoporous substrate has a porosity of about 60% to about 80%.

33. The implant of any one of claims 21-32, wherein the nanoporous substrate has a surface energy of about 40 milli Joule per square meter (mJ / m2) to about 60 mJ / m234. The implant of any one of claims 21-33, wherein the nanoporous substrate has a surface energy of 55 mJ / m235. The implant of any one of claims 21-34, wherein the implant is biodegradable.